Therapeutic Potential of TLR8 Agonist GS‐9688 (Selgantolimod) in Chronic Hepatitis B : Remodeling of Antiviral and Regulatory Mediators

Author:

Amin Oliver E.1ORCID,Colbeck Emily J.1,Daffis Stephane2,Khan Shahzada2,Ramakrishnan Dhivya2,Pattabiraman Divya2,Chu Ruth2,Micolochick Steuer Holly2,Lehar Sophie2,Peiser Leanne2,Palazzo Adam2,Frey Christian2,Davies Jessica1,Javanbakht Hassan2,Rosenberg William M.C.3,Fletcher Simon P.2ORCID,Maini Mala K.1ORCID,Pallett Laura J.1ORCID

Affiliation:

1. Division of Infection & Immunity Institute of Immunity & Transplantation University College London London United Kingdom

2. Gilead Sciences Inc. Foster City CA

3. Institute for Liver and Digestive Health University College London London United Kingdom

Funder

Gilead Sciences

Publisher

Wiley

Subject

Hepatology

Reference55 articles.

1. World Health Organization Global Hepatitis Programme.Global hepatitis report.2017.http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455‐eng.pdf?ua=1. Accessed May 21 2020.

2. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

3. HBV cure: why, how, when?

4. Adaptive immunity in HBV infection

5. Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3